Bayer HealthCare helps to drive Bayer group growth in Q2 2012

Bayer HealthCare has experienced strong business growth during the second quarter of 2012, according to the Bayer group's latest fiscal report.

The business unit's sales rose by ten percent year on year to 4.63 billion euros (3.65 billion pounds), with both the pharmaceuticals and consumer health operations playing a role in this growth.

Key products that contributed to this improvement include the recently-launched Xarelto and other drugs such as Mirena, Betaferon and Nexavar, as well as consumer care offering such as Bephanthen and Aleve.

In total, the Bayer group achieved quarterly sales of 10.2 billion euros, a strong performance that has prompted the firm to raise its guidance for the remainder of 2012.

Management board chairman Dr Marijn Dekkers said: "Following the good business performance in the first half of 2012, especially at CropScience and HealthCare, we are also confident for the second half of the year."

Last week, the company received a National Institute for Health and Clinical Excellence recommendation for its drug Xarelto to be used among NHS deep vein thrombosis patients.